After-Hours Stock Movers: Ardelyx shares tumbles 73%

287
47
Favorite

After-Hours Stock Movers: Ardelyx shares tumbles 73%

StreetInsider2021-07-20

Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the "FDA") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

287

Report

Comment（47）

Meshaarias72
·2021-07-20
Like n comment pls
Reply
1
Report
BokWoon
·2021-07-20
[Thinking]
Reply
2
Report
randy126
·2021-07-20
Pls check decide then acr
Reply
3
Report
Fold Replies
- Meshaarias72:
  Y
  2021-07-20
  Reply
  Report
elynzj
·2021-07-20
Ok
Reply
6
Report
Fold Replies
- Wenikho:
  Ok
  2021-07-20
  Reply
  Report
Stanpai
·2021-07-20
Like
Reply
4
Report
psion
·2021-07-20
Like and comment pl
Reply
5
Report
Fold Replies
- jazzzy:
  sure.......
  2021-07-20
  Reply
  Report
- Stanpai:
  done
  2021-07-20
  Reply
  Report
Rado14
·2021-07-20
Hmmmm
Reply
5
Report
JohnL
·2021-07-20
Wow
Reply
6
Report
nyse
·2021-07-20
This is bad
Reply
8
Report
Weeliam
·2021-07-20
Like
Reply
9
Report
Fold Replies
- psion:
  done
  2021-07-20
  Reply
  Report
Zx1008
·2021-07-20
Yes
Reply
6
Report
Lululimmok
·2021-07-20
Like thx
Reply
3
Report
小虎一飞冲天
·2021-07-20
Like pls. Thanks.
Reply
6
Report
Fold Replies
- Lululimmok:
  Ok
  2021-07-20
  Reply
  Report
玉树临风英俊
·2021-07-20
?
Reply
5
Report
Fold Replies
- Yuanecute:
  okkk?
  2021-07-20
  Reply
  Report
J0E
·2021-07-20
Please like and comment, thanks!
Reply
2
Report
Fold Replies
- Huathk:
  Gd
  2021-07-20
  Reply
  Report
- J0E:
  Thanks!
  2021-07-20
  Reply
  Report
A68
·2021-07-20
Hard hard
Reply
3
Report
fidllama
·2021-07-20
ok
Reply
3
Report
tkj
·2021-07-20
Such is the vulnerability of pharmaceutical companies. Any rejection at the govt level will cause the shares to plummet. On the other hand, announcement of govt acceptance will cause the stock to jump.....casino effect.....
Reply
3
Report
leekanghao
·2021-07-20
Read!
Reply
2
Report
Dcagency
·2021-07-20
[Surprised]
Reply
4
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2152652796?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-07-20 07:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2152652796","market":"us","top_or_hot":-1,"title":"After-Hours Stock Movers: Ardelyx shares tumbles 73%","media":"StreetInsider","content":"<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Source Link</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ardelyx shares tumbles 73% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ardelyx shares tumbles 73% \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18693676><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMRX","symbol_name":"Amneal Pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=18693676","article_id":"2152652796","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2152652796","pubTimestamp":1626738000,"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","IBM":"IBM","CCK":"皇冠控股","ARDX":"Ardelyx","RCUS":"Arcus Biosciences Inc.","PPG":"PPG工业"},"translate_title":"盘后股票市场：Ardelyx股价暴跌73%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRX":0.9,"ARDX":0.9,"CCK":0.9,"IBM":0.9,"PPG":0.9,"RCUS":0.9},"content_text":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.\nArcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.\nPPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.\nCrown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.\nIBM (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":178969139,"gmtCreate":1626782284621,"gmtModify":1703765059757,"author":{"id":"3577781617271173","authorId":"3577781617271173","authorIdStr":"3577781617271173","name":"Meshaarias72","avatar":"https://static.tigerbbs.com/c5282cda6a9d3948fc067b21adcb578c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577781617271173"},"htmlText":"Like n comment pls","listText":"Like n comment pls","text":"Like n comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/178969139","repostId":2152652796,"repostType":4,"repost":{"id":"2152652796","pubTimestamp":1626738000,"share":"https://ttm.financial/m/news/2152652796?lang=&edition=fundamental","pubTime":"2021-07-20 07:40","market":"us","language":"en","title":"After-Hours Stock Movers: Ardelyx shares tumbles 73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2152652796","media":"StreetInsider","summary":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration","content":"<p><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.</p>\n<p>Arcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.</p>\n<p>PPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.</p>\n<p><a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a> (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.</p>\n<p>Crown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.</p>\n<p><a href=\"https://laohu8.com/S/IBM\">IBM</a> (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ardelyx shares tumbles 73% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ardelyx shares tumbles 73% \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18693676><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","IBM":"IBM","RCUS":"Arcus Biosciences Inc.","ARDX":"Ardelyx","PPG":"PPG工业","CCK":"皇冠控股"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18693676","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152652796","content_text":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.\nArcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.\nPPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.\nCrown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.\nIBM (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":178037313,"gmtCreate":1626771110532,"gmtModify":1703764881939,"author":{"id":"3586346457808493","authorId":"3586346457808493","authorIdStr":"3586346457808493","name":"BokWoon","avatar":"https://static.tigerbbs.com/33c54abe9712d43f005ec31ac4eb5e90","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3586346457808493"},"htmlText":"[Thinking]&nbsp;","listText":"[Thinking]&nbsp;","text":"[Thinking]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/178037313","repostId":2152652796,"repostType":4,"repost":{"id":"2152652796","pubTimestamp":1626738000,"share":"https://ttm.financial/m/news/2152652796?lang=&edition=fundamental","pubTime":"2021-07-20 07:40","market":"us","language":"en","title":"After-Hours Stock Movers: Ardelyx shares tumbles 73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2152652796","media":"StreetInsider","summary":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration","content":"<p><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.</p>\n<p>Arcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.</p>\n<p>PPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.</p>\n<p><a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a> (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.</p>\n<p>Crown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.</p>\n<p><a href=\"https://laohu8.com/S/IBM\">IBM</a> (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ardelyx shares tumbles 73% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ardelyx shares tumbles 73% \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18693676><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","IBM":"IBM","RCUS":"Arcus Biosciences Inc.","ARDX":"Ardelyx","PPG":"PPG工业","CCK":"皇冠控股"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18693676","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152652796","content_text":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.\nArcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.\nPPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.\nCrown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.\nIBM (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":171461278,"gmtCreate":1626756976894,"gmtModify":1703764631290,"author":{"id":"4087541322766510","authorId":"4087541322766510","authorIdStr":"4087541322766510","name":"randy126","avatar":"https://static.tigerbbs.com/6306d136c23cfaed5f8d1af2007ebb7a","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4087541322766510"},"htmlText":"Pls check&nbsp; decide then acr","listText":"Pls check&nbsp; decide then acr","text":"Pls check decide then acr","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/171461278","repostId":2152652796,"repostType":4,"repost":{"id":"2152652796","pubTimestamp":1626738000,"share":"https://ttm.financial/m/news/2152652796?lang=&edition=fundamental","pubTime":"2021-07-20 07:40","market":"us","language":"en","title":"After-Hours Stock Movers: Ardelyx shares tumbles 73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2152652796","media":"StreetInsider","summary":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration","content":"<p><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.</p>\n<p>Arcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.</p>\n<p>PPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.</p>\n<p><a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a> (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.</p>\n<p>Crown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.</p>\n<p><a href=\"https://laohu8.com/S/IBM\">IBM</a> (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ardelyx shares tumbles 73% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ardelyx shares tumbles 73% \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18693676><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","IBM":"IBM","RCUS":"Arcus Biosciences Inc.","ARDX":"Ardelyx","PPG":"PPG工业","CCK":"皇冠控股"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18693676","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152652796","content_text":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.\nArcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.\nPPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.\nCrown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.\nIBM (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5272367,"gmtCreate":1626782293351,"gmtModify":1663231211830,"authorId":3577781617271173,"author":{"id":3577781617271173,"authorId":3577781617271173,"name":"Meshaarias72","avatar":"https://static.tigerbbs.com/c5282cda6a9d3948fc067b21adcb578c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":171461278,"type":1,"supId":0,"prevId":0,"content":"Y","text":"Y","html":"Y"}],"langContent":"EN"},{"id":171540568,"gmtCreate":1626752452654,"gmtModify":1703764526527,"author":{"id":"3584528872593052","authorId":"3584528872593052","authorIdStr":"3584528872593052","name":"elynzj","avatar":"https://static.tigerbbs.com/1eebec41932cb5587648b6ba43ac3e8b","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3584528872593052"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/171540568","repostId":2152652796,"repostType":4,"repost":{"id":"2152652796","pubTimestamp":1626738000,"share":"https://ttm.financial/m/news/2152652796?lang=&edition=fundamental","pubTime":"2021-07-20 07:40","market":"us","language":"en","title":"After-Hours Stock Movers: Ardelyx shares tumbles 73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2152652796","media":"StreetInsider","summary":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration","content":"<p><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.</p>\n<p>Arcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.</p>\n<p>PPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.</p>\n<p><a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a> (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.</p>\n<p>Crown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.</p>\n<p><a href=\"https://laohu8.com/S/IBM\">IBM</a> (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ardelyx shares tumbles 73% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ardelyx shares tumbles 73% \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18693676><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","IBM":"IBM","RCUS":"Arcus Biosciences Inc.","ARDX":"Ardelyx","PPG":"PPG工业","CCK":"皇冠控股"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18693676","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152652796","content_text":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.\nArcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.\nPPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.\nCrown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.\nIBM (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5269678,"gmtCreate":1626755846695,"gmtModify":1635225509600,"authorId":3583735307988740,"author":{"id":3583735307988740,"authorId":3583735307988740,"name":"Wenikho","avatar":"https://static.tigerbbs.com/48d673eefef20f75808048d78501a48f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":171540568,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":171555008,"gmtCreate":1626752238104,"gmtModify":1703764522001,"author":{"id":"3579339960508739","authorId":"3579339960508739","authorIdStr":"3579339960508739","name":"Stanpai","avatar":"https://static.tigerbbs.com/9d7937f5358a694015eb202f6a8282a3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579339960508739"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171555008","repostId":2152652796,"repostType":4,"repost":{"id":"2152652796","pubTimestamp":1626738000,"share":"https://ttm.financial/m/news/2152652796?lang=&edition=fundamental","pubTime":"2021-07-20 07:40","market":"us","language":"en","title":"After-Hours Stock Movers: Ardelyx shares tumbles 73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2152652796","media":"StreetInsider","summary":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration","content":"<p><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.</p>\n<p>Arcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.</p>\n<p>PPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.</p>\n<p><a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a> (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.</p>\n<p>Crown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.</p>\n<p><a href=\"https://laohu8.com/S/IBM\">IBM</a> (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ardelyx shares tumbles 73% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ardelyx shares tumbles 73% \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18693676><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","IBM":"IBM","RCUS":"Arcus Biosciences Inc.","ARDX":"Ardelyx","PPG":"PPG工业","CCK":"皇冠控股"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18693676","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152652796","content_text":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.\nArcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.\nPPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.\nCrown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.\nIBM (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":171551334,"gmtCreate":1626751948028,"gmtModify":1703764516341,"author":{"id":"3581845985051272","authorId":"3581845985051272","authorIdStr":"3581845985051272","name":"psion","avatar":"https://static.tigerbbs.com/ab2eccc9177a2c142fab5a37345bc343","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3581845985051272"},"htmlText":"Like and comment pl","listText":"Like and comment pl","text":"Like and comment pl","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/171551334","repostId":2152652796,"repostType":4,"repost":{"id":"2152652796","pubTimestamp":1626738000,"share":"https://ttm.financial/m/news/2152652796?lang=&edition=fundamental","pubTime":"2021-07-20 07:40","market":"us","language":"en","title":"After-Hours Stock Movers: Ardelyx shares tumbles 73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2152652796","media":"StreetInsider","summary":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration","content":"<p><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.</p>\n<p>Arcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.</p>\n<p>PPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.</p>\n<p><a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a> (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.</p>\n<p>Crown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.</p>\n<p><a href=\"https://laohu8.com/S/IBM\">IBM</a> (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ardelyx shares tumbles 73% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ardelyx shares tumbles 73% \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18693676><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","IBM":"IBM","RCUS":"Arcus Biosciences Inc.","ARDX":"Ardelyx","PPG":"PPG工业","CCK":"皇冠控股"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18693676","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152652796","content_text":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.\nArcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.\nPPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.\nCrown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.\nIBM (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5269391,"gmtCreate":1626753798992,"gmtModify":1663231195645,"authorId":3581506801937793,"author":{"id":3581506801937793,"authorId":3581506801937793,"name":"jazzzy","avatar":"https://static.tigerbbs.com/736d94d3e7bf42768178b76a7657b611","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":171551334,"type":1,"supId":0,"prevId":0,"content":"sure.......","text":"sure.......","html":"sure......."},{"id":5269176,"gmtCreate":1626752245400,"gmtModify":1663231193249,"authorId":3579339960508739,"author":{"id":3579339960508739,"authorId":3579339960508739,"name":"Stanpai","avatar":"https://static.tigerbbs.com/9d7937f5358a694015eb202f6a8282a3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":171551334,"type":1,"supId":0,"prevId":0,"content":"<u>done</u>","text":"<u>done</u>","html":"<u>done</u>"}],"langContent":"EN"},{"id":171522567,"gmtCreate":1626751550459,"gmtModify":1703764507287,"author":{"id":"3586426911844759","authorId":"3586426911844759","authorIdStr":"3586426911844759","name":"Rado14","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586426911844759"},"htmlText":"Hmmmm","listText":"Hmmmm","text":"Hmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171522567","repostId":2152652796,"repostType":4,"repost":{"id":"2152652796","pubTimestamp":1626738000,"share":"https://ttm.financial/m/news/2152652796?lang=&edition=fundamental","pubTime":"2021-07-20 07:40","market":"us","language":"en","title":"After-Hours Stock Movers: Ardelyx shares tumbles 73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2152652796","media":"StreetInsider","summary":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration","content":"<p><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.</p>\n<p>Arcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.</p>\n<p>PPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.</p>\n<p><a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a> (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.</p>\n<p>Crown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.</p>\n<p><a href=\"https://laohu8.com/S/IBM\">IBM</a> (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ardelyx shares tumbles 73% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ardelyx shares tumbles 73% \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18693676><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","IBM":"IBM","RCUS":"Arcus Biosciences Inc.","ARDX":"Ardelyx","PPG":"PPG工业","CCK":"皇冠控股"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18693676","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152652796","content_text":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.\nArcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.\nPPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.\nCrown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.\nIBM (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":171587498,"gmtCreate":1626750743614,"gmtModify":1703764484370,"author":{"id":"3570369418287680","authorId":"3570369418287680","authorIdStr":"3570369418287680","name":"JohnL","avatar":"https://community-static.tradeup.com/news/20db2fa4f65cb04a8d837d400a1b5d7b","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"3570369418287680"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171587498","repostId":2152652796,"repostType":4,"repost":{"id":"2152652796","pubTimestamp":1626738000,"share":"https://ttm.financial/m/news/2152652796?lang=&edition=fundamental","pubTime":"2021-07-20 07:40","market":"us","language":"en","title":"After-Hours Stock Movers: Ardelyx shares tumbles 73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2152652796","media":"StreetInsider","summary":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration","content":"<p><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.</p>\n<p>Arcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.</p>\n<p>PPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.</p>\n<p><a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a> (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.</p>\n<p>Crown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.</p>\n<p><a href=\"https://laohu8.com/S/IBM\">IBM</a> (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ardelyx shares tumbles 73% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ardelyx shares tumbles 73% \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18693676><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","IBM":"IBM","RCUS":"Arcus Biosciences Inc.","ARDX":"Ardelyx","PPG":"PPG工业","CCK":"皇冠控股"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18693676","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152652796","content_text":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.\nArcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.\nPPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.\nCrown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.\nIBM (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":171517238,"gmtCreate":1626750203724,"gmtModify":1703764470412,"author":{"id":"4087337498175360","authorId":"4087337498175360","authorIdStr":"4087337498175360","name":"nyse","avatar":"https://static.tigerbbs.com/e034b6608722ef1e0771aba89b643053","vip":1,"crmLevel":1,"crmLevelSwitch":1,"idStr":"4087337498175360"},"htmlText":"This is bad","listText":"This is bad","text":"This is bad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171517238","repostId":2152652796,"repostType":4,"repost":{"id":"2152652796","pubTimestamp":1626738000,"share":"https://ttm.financial/m/news/2152652796?lang=&edition=fundamental","pubTime":"2021-07-20 07:40","market":"us","language":"en","title":"After-Hours Stock Movers: Ardelyx shares tumbles 73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2152652796","media":"StreetInsider","summary":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration","content":"<p><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.</p>\n<p>Arcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.</p>\n<p>PPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.</p>\n<p><a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a> (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.</p>\n<p>Crown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.</p>\n<p><a href=\"https://laohu8.com/S/IBM\">IBM</a> (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ardelyx shares tumbles 73% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ardelyx shares tumbles 73% \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18693676><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","IBM":"IBM","RCUS":"Arcus Biosciences Inc.","ARDX":"Ardelyx","PPG":"PPG工业","CCK":"皇冠控股"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18693676","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152652796","content_text":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.\nArcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.\nPPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.\nCrown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.\nIBM (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":171518486,"gmtCreate":1626750019245,"gmtModify":1703764463179,"author":{"id":"3573939804764668","authorId":"3573939804764668","authorIdStr":"3573939804764668","name":"Weeliam","avatar":"https://static.tigerbbs.com/018f438aee56ca77deea3cb08e1bfa81","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573939804764668"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/171518486","repostId":2152652796,"repostType":4,"repost":{"id":"2152652796","pubTimestamp":1626738000,"share":"https://ttm.financial/m/news/2152652796?lang=&edition=fundamental","pubTime":"2021-07-20 07:40","market":"us","language":"en","title":"After-Hours Stock Movers: Ardelyx shares tumbles 73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2152652796","media":"StreetInsider","summary":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration","content":"<p><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.</p>\n<p>Arcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.</p>\n<p>PPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.</p>\n<p><a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a> (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.</p>\n<p>Crown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.</p>\n<p><a href=\"https://laohu8.com/S/IBM\">IBM</a> (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ardelyx shares tumbles 73% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ardelyx shares tumbles 73% \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18693676><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","IBM":"IBM","RCUS":"Arcus Biosciences Inc.","ARDX":"Ardelyx","PPG":"PPG工业","CCK":"皇冠控股"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18693676","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152652796","content_text":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.\nArcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.\nPPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.\nCrown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.\nIBM (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5269143,"gmtCreate":1626751961037,"gmtModify":1663231192761,"authorId":3581845985051272,"author":{"id":3581845985051272,"authorId":3581845985051272,"name":"psion","avatar":"https://static.tigerbbs.com/ab2eccc9177a2c142fab5a37345bc343","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":171518486,"type":1,"supId":0,"prevId":0,"content":"<u>done</u>","text":"<u>done</u>","html":"<u>done</u>"}],"langContent":"EN"},{"id":171510882,"gmtCreate":1626749762546,"gmtModify":1703764456454,"author":{"id":"3581823706139517","authorId":"3581823706139517","authorIdStr":"3581823706139517","name":"Zx1008","avatar":"https://static.tigerbbs.com/fdb3cce08a739e317d4fb462983c1cee","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3581823706139517"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171510882","repostId":2152652796,"repostType":4,"repost":{"id":"2152652796","pubTimestamp":1626738000,"share":"https://ttm.financial/m/news/2152652796?lang=&edition=fundamental","pubTime":"2021-07-20 07:40","market":"us","language":"en","title":"After-Hours Stock Movers: Ardelyx shares tumbles 73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2152652796","media":"StreetInsider","summary":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration","content":"<p><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.</p>\n<p>Arcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.</p>\n<p>PPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.</p>\n<p><a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a> (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.</p>\n<p>Crown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.</p>\n<p><a href=\"https://laohu8.com/S/IBM\">IBM</a> (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ardelyx shares tumbles 73% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ardelyx shares tumbles 73% \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18693676><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","IBM":"IBM","RCUS":"Arcus Biosciences Inc.","ARDX":"Ardelyx","PPG":"PPG工业","CCK":"皇冠控股"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18693676","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152652796","content_text":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.\nArcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.\nPPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.\nCrown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.\nIBM (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":171539130,"gmtCreate":1626749410120,"gmtModify":1703764444641,"author":{"id":"3582010686766598","authorId":"3582010686766598","authorIdStr":"3582010686766598","name":"Lululimmok","avatar":"https://static.tigerbbs.com/fcb4102cffc589f4ab17c35dd6217cf0","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3582010686766598"},"htmlText":"Like thx","listText":"Like thx","text":"Like thx","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171539130","repostId":2152652796,"repostType":4,"repost":{"id":"2152652796","pubTimestamp":1626738000,"share":"https://ttm.financial/m/news/2152652796?lang=&edition=fundamental","pubTime":"2021-07-20 07:40","market":"us","language":"en","title":"After-Hours Stock Movers: Ardelyx shares tumbles 73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2152652796","media":"StreetInsider","summary":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration","content":"<p><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.</p>\n<p>Arcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.</p>\n<p>PPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.</p>\n<p><a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a> (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.</p>\n<p>Crown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.</p>\n<p><a href=\"https://laohu8.com/S/IBM\">IBM</a> (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ardelyx shares tumbles 73% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ardelyx shares tumbles 73% \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18693676><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","IBM":"IBM","RCUS":"Arcus Biosciences Inc.","ARDX":"Ardelyx","PPG":"PPG工业","CCK":"皇冠控股"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18693676","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152652796","content_text":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.\nArcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.\nPPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.\nCrown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.\nIBM (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":171596779,"gmtCreate":1626749168291,"gmtModify":1703764435777,"author":{"id":"3582098623642517","authorId":"3582098623642517","authorIdStr":"3582098623642517","name":"小虎一飞冲天","avatar":"https://static.tigerbbs.com/1a55a61195830e019abf5d3cc69681b9","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3582098623642517"},"htmlText":"Like pls. Thanks.","listText":"Like pls. Thanks.","text":"Like pls. Thanks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/171596779","repostId":2152652796,"repostType":4,"repost":{"id":"2152652796","pubTimestamp":1626738000,"share":"https://ttm.financial/m/news/2152652796?lang=&edition=fundamental","pubTime":"2021-07-20 07:40","market":"us","language":"en","title":"After-Hours Stock Movers: Ardelyx shares tumbles 73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2152652796","media":"StreetInsider","summary":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration","content":"<p><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.</p>\n<p>Arcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.</p>\n<p>PPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.</p>\n<p><a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a> (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.</p>\n<p>Crown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.</p>\n<p><a href=\"https://laohu8.com/S/IBM\">IBM</a> (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ardelyx shares tumbles 73% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ardelyx shares tumbles 73% \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18693676><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","IBM":"IBM","RCUS":"Arcus Biosciences Inc.","ARDX":"Ardelyx","PPG":"PPG工业","CCK":"皇冠控股"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18693676","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152652796","content_text":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.\nArcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.\nPPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.\nCrown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.\nIBM (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5268699,"gmtCreate":1626749441936,"gmtModify":1663231190545,"authorId":3582010686766598,"author":{"id":3582010686766598,"authorId":3582010686766598,"name":"Lululimmok","avatar":"https://static.tigerbbs.com/fcb4102cffc589f4ab17c35dd6217cf0","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":171596779,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":171599164,"gmtCreate":1626748939958,"gmtModify":1703764430026,"author":{"id":"3580076354872466","authorId":"3580076354872466","authorIdStr":"3580076354872466","name":"玉树临风英俊","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3580076354872466"},"htmlText":"?&nbsp;","listText":"?&nbsp;","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/171599164","repostId":2152652796,"repostType":4,"repost":{"id":"2152652796","pubTimestamp":1626738000,"share":"https://ttm.financial/m/news/2152652796?lang=&edition=fundamental","pubTime":"2021-07-20 07:40","market":"us","language":"en","title":"After-Hours Stock Movers: Ardelyx shares tumbles 73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2152652796","media":"StreetInsider","summary":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration","content":"<p><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.</p>\n<p>Arcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.</p>\n<p>PPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.</p>\n<p><a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a> (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.</p>\n<p>Crown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.</p>\n<p><a href=\"https://laohu8.com/S/IBM\">IBM</a> (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ardelyx shares tumbles 73% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ardelyx shares tumbles 73% \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18693676><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","IBM":"IBM","RCUS":"Arcus Biosciences Inc.","ARDX":"Ardelyx","PPG":"PPG工业","CCK":"皇冠控股"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18693676","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152652796","content_text":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.\nArcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.\nPPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.\nCrown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.\nIBM (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5269274,"gmtCreate":1626752956574,"gmtModify":1663231199247,"authorId":3583210195403389,"author":{"id":3583210195403389,"authorId":3583210195403389,"name":"Yuanecute","avatar":"https://static.tigerbbs.com/b16771be0bfff1b89dc4e942803ce2c2","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":171599164,"type":1,"supId":0,"prevId":0,"content":"okkk?","text":"okkk?","html":"okkk?"}],"langContent":"EN"},{"id":171276735,"gmtCreate":1626748361427,"gmtModify":1703764408956,"author":{"id":"3574543568455317","authorId":"3574543568455317","authorIdStr":"3574543568455317","name":"J0E","avatar":"https://static.tigerbbs.com/99608013a269b8a017f9553f07dd5f19","vip":1,"hat":"https://static.tigerbbs.com/7b75ce0c34afff716602792a5d0929dd","crmLevel":2,"crmLevelSwitch":0,"idStr":"3574543568455317"},"htmlText":"Please like and comment, thanks!","listText":"Please like and comment, thanks!","text":"Please like and comment, thanks!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/171276735","repostId":2152652796,"repostType":4,"repost":{"id":"2152652796","pubTimestamp":1626738000,"share":"https://ttm.financial/m/news/2152652796?lang=&edition=fundamental","pubTime":"2021-07-20 07:40","market":"us","language":"en","title":"After-Hours Stock Movers: Ardelyx shares tumbles 73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2152652796","media":"StreetInsider","summary":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration","content":"<p><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.</p>\n<p>Arcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.</p>\n<p>PPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.</p>\n<p><a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a> (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.</p>\n<p>Crown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.</p>\n<p><a href=\"https://laohu8.com/S/IBM\">IBM</a> (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ardelyx shares tumbles 73% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ardelyx shares tumbles 73% \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18693676><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","IBM":"IBM","RCUS":"Arcus Biosciences Inc.","ARDX":"Ardelyx","PPG":"PPG工业","CCK":"皇冠控股"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18693676","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152652796","content_text":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.\nArcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.\nPPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.\nCrown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.\nIBM (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5271187,"gmtCreate":1626770465248,"gmtModify":1663231208438,"authorId":3573472992263411,"author":{"id":3573472992263411,"authorId":3573472992263411,"name":"Huathk","avatar":"https://static.tigerbbs.com/43c7168c646d9ea6805194ed0003f1cc","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":171276735,"type":1,"supId":0,"prevId":0,"content":"Gd","text":"Gd","html":"Gd"},{"id":5271192,"gmtCreate":1626770501435,"gmtModify":1631896515728,"authorId":3574543568455317,"author":{"id":3574543568455317,"authorId":3574543568455317,"name":"J0E","avatar":"https://static.tigerbbs.com/99608013a269b8a017f9553f07dd5f19","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":171276735,"type":1,"supId":5271187,"prevId":0,"content":"Thanks!","text":"Thanks!","html":"Thanks!"}],"langContent":"EN"},{"id":171258008,"gmtCreate":1626747363104,"gmtModify":1703764380239,"author":{"id":"3576813955258325","authorId":"3576813955258325","authorIdStr":"3576813955258325","name":"A68","avatar":"https://static.tigerbbs.com/d209afa981c29a4dc34bd7c1c986fb4a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576813955258325"},"htmlText":"Hard hard","listText":"Hard hard","text":"Hard hard","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171258008","repostId":2152652796,"repostType":4,"repost":{"id":"2152652796","pubTimestamp":1626738000,"share":"https://ttm.financial/m/news/2152652796?lang=&edition=fundamental","pubTime":"2021-07-20 07:40","market":"us","language":"en","title":"After-Hours Stock Movers: Ardelyx shares tumbles 73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2152652796","media":"StreetInsider","summary":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration","content":"<p><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.</p>\n<p>Arcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.</p>\n<p>PPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.</p>\n<p><a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a> (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.</p>\n<p>Crown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.</p>\n<p><a href=\"https://laohu8.com/S/IBM\">IBM</a> (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ardelyx shares tumbles 73% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ardelyx shares tumbles 73% \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18693676><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","IBM":"IBM","RCUS":"Arcus Biosciences Inc.","ARDX":"Ardelyx","PPG":"PPG工业","CCK":"皇冠控股"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18693676","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152652796","content_text":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.\nArcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.\nPPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.\nCrown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.\nIBM (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":171227052,"gmtCreate":1626747166276,"gmtModify":1703764373858,"author":{"id":"3577494565516476","authorId":"3577494565516476","authorIdStr":"3577494565516476","name":"fidllama","avatar":"https://community-static.tradeup.com/news/df43ce0653d590390fc3431ea46d58ef","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3577494565516476"},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171227052","repostId":2152652796,"repostType":4,"repost":{"id":"2152652796","pubTimestamp":1626738000,"share":"https://ttm.financial/m/news/2152652796?lang=&edition=fundamental","pubTime":"2021-07-20 07:40","market":"us","language":"en","title":"After-Hours Stock Movers: Ardelyx shares tumbles 73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2152652796","media":"StreetInsider","summary":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration","content":"<p><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.</p>\n<p>Arcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.</p>\n<p>PPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.</p>\n<p><a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a> (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.</p>\n<p>Crown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.</p>\n<p><a href=\"https://laohu8.com/S/IBM\">IBM</a> (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ardelyx shares tumbles 73% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ardelyx shares tumbles 73% \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18693676><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","IBM":"IBM","RCUS":"Arcus Biosciences Inc.","ARDX":"Ardelyx","PPG":"PPG工业","CCK":"皇冠控股"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18693676","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152652796","content_text":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.\nArcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.\nPPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.\nCrown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.\nIBM (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":171266855,"gmtCreate":1626746649477,"gmtModify":1703764354363,"author":{"id":"3582020830270271","authorId":"3582020830270271","authorIdStr":"3582020830270271","name":"tkj","avatar":"https://static.tigerbbs.com/b4db3635974ce189ed8129eca6b5b618","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3582020830270271"},"htmlText":"Such is the vulnerability of pharmaceutical companies. Any rejection at the govt level will cause the shares to plummet. On the other hand, announcement of govt acceptance will cause the stock to jump.....casino effect.....","listText":"Such is the vulnerability of pharmaceutical companies. Any rejection at the govt level will cause the shares to plummet. On the other hand, announcement of govt acceptance will cause the stock to jump.....casino effect.....","text":"Such is the vulnerability of pharmaceutical companies. Any rejection at the govt level will cause the shares to plummet. On the other hand, announcement of govt acceptance will cause the stock to jump.....casino effect.....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171266855","repostId":2152652796,"repostType":4,"repost":{"id":"2152652796","pubTimestamp":1626738000,"share":"https://ttm.financial/m/news/2152652796?lang=&edition=fundamental","pubTime":"2021-07-20 07:40","market":"us","language":"en","title":"After-Hours Stock Movers: Ardelyx shares tumbles 73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2152652796","media":"StreetInsider","summary":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration","content":"<p><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.</p>\n<p>Arcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.</p>\n<p>PPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.</p>\n<p><a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a> (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.</p>\n<p>Crown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.</p>\n<p><a href=\"https://laohu8.com/S/IBM\">IBM</a> (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ardelyx shares tumbles 73% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ardelyx shares tumbles 73% \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18693676><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","IBM":"IBM","RCUS":"Arcus Biosciences Inc.","ARDX":"Ardelyx","PPG":"PPG工业","CCK":"皇冠控股"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18693676","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152652796","content_text":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.\nArcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.\nPPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.\nCrown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.\nIBM (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":171269113,"gmtCreate":1626746534732,"gmtModify":1703764348352,"author":{"id":"3583978426873835","authorId":"3583978426873835","authorIdStr":"3583978426873835","name":"leekanghao","avatar":"https://static.tigerbbs.com/3c1122e49e06c919b85c00976e928d03","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583978426873835"},"htmlText":"Read!","listText":"Read!","text":"Read!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171269113","repostId":2152652796,"repostType":4,"repost":{"id":"2152652796","pubTimestamp":1626738000,"share":"https://ttm.financial/m/news/2152652796?lang=&edition=fundamental","pubTime":"2021-07-20 07:40","market":"us","language":"en","title":"After-Hours Stock Movers: Ardelyx shares tumbles 73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2152652796","media":"StreetInsider","summary":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration","content":"<p><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.</p>\n<p>Arcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.</p>\n<p>PPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.</p>\n<p><a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a> (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.</p>\n<p>Crown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.</p>\n<p><a href=\"https://laohu8.com/S/IBM\">IBM</a> (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ardelyx shares tumbles 73% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ardelyx shares tumbles 73% \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18693676><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","IBM":"IBM","RCUS":"Arcus Biosciences Inc.","ARDX":"Ardelyx","PPG":"PPG工业","CCK":"皇冠控股"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18693676","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152652796","content_text":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.\nArcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.\nPPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.\nCrown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.\nIBM (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":171287488,"gmtCreate":1626746483044,"gmtModify":1703764350133,"author":{"id":"3557142354281361","authorId":"3557142354281361","authorIdStr":"3557142354281361","name":"Dcagency","avatar":"https://static.tigerbbs.com/811d507c3458decd0eacd9028472dcf4","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3557142354281361"},"htmlText":"[Surprised]&nbsp;","listText":"[Surprised]&nbsp;","text":"[Surprised]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171287488","repostId":2152652796,"repostType":4,"repost":{"id":"2152652796","pubTimestamp":1626738000,"share":"https://ttm.financial/m/news/2152652796?lang=&edition=fundamental","pubTime":"2021-07-20 07:40","market":"us","language":"en","title":"After-Hours Stock Movers: Ardelyx shares tumbles 73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2152652796","media":"StreetInsider","summary":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration","content":"<p><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.</p>\n<p>Arcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.</p>\n<p>PPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.</p>\n<p><a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a> (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.</p>\n<p>Crown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.</p>\n<p><a href=\"https://laohu8.com/S/IBM\">IBM</a> (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ardelyx shares tumbles 73% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ardelyx shares tumbles 73% \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18693676><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18693676\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","IBM":"IBM","RCUS":"Arcus Biosciences Inc.","ARDX":"Ardelyx","PPG":"PPG工业","CCK":"皇冠控股"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18693676","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152652796","content_text":"Ardelyx, Inc. (Nasdaq: ARDX) 73% LOWER; received a letter from the U.S. Food and Drug Administration (the \"FDA\") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application (\"NDA\") for the control of serum phosphorus in adult patients with chronic kidney disease (\"CKD\") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied.\nArcus Biosciences (NYSE: RCUS) 7% LOWER; announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021.\nPPG Industries (NYSE: PPG) 5.9% LOWER; reported Q2 EPS of $1.94, $0.26 worse than the analyst estimate of $2.20. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.33 billion.\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) 5.8% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.\nCrown Holdings (NYSE: CCK) 4.6% HIGHER; reported Q2 EPS of $2.14, $0.37 better than the analyst estimate of $1.77. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.97 billion. Crown Holdings sees Q3 2021 EPS of $1.90-$2.00, versus the consensus of $1.69. Crown Holdings sees FY2021 EPS of $7.30-$7.40, versus the consensus of $6.86.\nIBM (NYSE: IBM) 3% HIGHER; reported Q2 EPS of $2.33, $0.04 better than the analyst estimate of $2.29. Revenue for the quarter came in at $18.7 billion versus the consensus estimate of $18.29 billion. The company expects to grow revenue for the full year 2021 based on mid-July 2021 foreign exchange rates. The company continues to expect adjusted free cash flow of $11 billion to $12 billion in 2021. Adjusted free cash flow expectations exclude approximately $3 billion of cash impacts from the company’s structural actions initiated in the fourth quarter of 2020 and the transaction costs associated with the separation of Kyndryl.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":287,"commentSize":47,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}